BrainMap

Adrian Trifa

- UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU"

Researcher | Teaching staff

Expertise & keywords

Massively parallel high-throughput sequencing for the identification of microRNAs differentially expressed between the metastatic site and the origin Call name: Projects for Young Research Teams - RUTE -2014 call
PN-II-RU-TE-2014-4-1783 2015 - 2017

Role in this project:

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO)

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO)

Project website: http://etixscientific.eu/cupmir/index.html

Abstract:

Almost one every three patients with advanced tumors have distant metastasis at the time of clinical diagnosis. For the most cases, the primary tumor site is identified within a few days, after other investigations such as modern imaging procedures and immunohistochemical staining of the biopsy. But for some patients, the primary lesion is never found. These cases are called metastases of unknown primary origin, very difficult to manage by physicians due to the absence of a standard-of-care for the initial therapeutic regimen, as well as due to the impossibility to include these cases in randomized clinical trials.

The primary tumor most often remains undetectable despite state-of-the-art techniques in clinical diagnostics and pathology analysis of the secondary tumor site.. Immunohistochemistry has improved the diagnostics of CUPs, but these still remain a major diagnostic issue . As short non-coding RNAs with regulatory functions named microRNA (miRNA) are emerging as highly specific biomarkers of the initial malignant cell, the aim of the current grant proposal is to identify the patterns of expression of various microRNAs that correlate with the tissue of origin for CUPs, using massively parallel high-throughput DNA sequencing, followed by validation with in situ hybridization (ISH) and RT-PCR.

The impact of the constitutional variation at the TERT, TET2 and MYB/HBS1L loci on the occurrence of the non-BCR-ABL myeloproliferative neoplasms Call name: Projects for Young Research Teams - RUTE -2014 call
PN-II-RU-TE-2014-4-0758 2015 - 2017

Role in this project:

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO)

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO)

Project website: http://www.granturi.umfcluj.ro/trifa/

Abstract:

The classical non-BCR-ABL myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia and primary myelofibrosis) are usually characterized by the acquisition of specific somatic mutations (JAK2 V617F, MPL and CALR). The only proven factor regarding the genetic predisposition to these diseases is the JAK2 46/1 haplotype, as we and others demonstrated. This project continues the research we already made on these diseases. The team that I propose aims to evaluate the contribution of new constitutional variants, namely TERT rs2736100, TET2 rs4698934 și MYB/HBS1L rs9376093 in the occurrence of the three non-BCR-ABL myeloproliferative neoplasms – polycythemia vera, essential thrombocythemia and primary myelofibrosis, their associated somatic mutations – JAK2 V617F, MPL and CALR, and their complications, on a representative study group – 400 patients and 200 controls. The population attributable fraction will be calculated for each polymorphism in part. The end-product of this project will be a mathematical model in predicting the occurrence of the non-BCR-ABL myeloproliferative neoplasms, taking into account phenotypes the TERT rs2736100, TET2 rs4698934 și MYB/HBS1L rs9376093 polymorphisms and the JAK2 46/1 haplotype. This model will serve to the international scientific community working on the hematological malignancies, in particular and on malignancies, in general.

FILE DESCRIPTION	DOCUMENT
List of research grants as project coordinator or partner team leader
Significant R&D projects for enterprises, as project manager
R&D activities in enterprises
Peer-review activity for international programs/projects